Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.

Accleron engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases.

Acceleron Pharma was founded in 2004 in Cambridge, Massachusetts as a Delaware corporation; the original name was Phoenix Pharma. The founders were scientists Jasbir Seehra, Tom Maniatis, Mark Ptashne & Wylie Vale. The headquartered in Cambridge, Massachusetts.

Accleron products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis.

Accleron develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. 

Accleron is backed by top-tier investors including Celgene, Venrock, OrbiMed, Bessemer Venture Partners among others.